Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00603031|
Recruitment Status : Completed
First Posted : January 28, 2008
Last Update Posted : January 21, 2011
|Condition or disease||Intervention/treatment|
|Type-1 Diabetes Mellitus||Other: glucagon like peptide -1 Other: NaCl Other: glucose dependent insulinotropic polypeptide|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Effect of GLP-1 and GIP on the Maximal Insulin Secretory Capacity in Type-1 Diabetes Mellitus|
|Study Start Date :||January 2008|
|Primary Completion Date :||June 2008|
|Study Completion Date :||June 2008|
time -30-90 min: Continuous infusion with GLP-1 (1,2pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
Other: glucagon like peptide -1
continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
Placebo Comparator: NaCl
time -30-90 min: Continuous infusion with NaCl time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
infusion with NaCl for 120 minutes as placebo-arm
time -30-90 min: Continuous infusion with GIP-1 (3,6pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
Other: glucose dependent insulinotropic polypeptide
continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
- phase insulin response and phase insulin response measured as incremental area under the curve from 0-10 minutes and incremental area under the curve from 10-45 minutes respectively after iv glucose [ Time Frame: 2 hours ]
- maximal insulin response defined as mean insulin at time 47 and 49 minutes (2 and 4 minutes after infusion of L-Arginine) [ Time Frame: 2 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00603031
|Dept. of Endocrinology, Hvidovre Hospital|
|Copenhagen, Denmark, 2650|
|Principal Investigator:||Urd Kielgast, MD||unafilliated|